The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
RNA-based therapeutics: an overview and prospectus
Y Zhu, L Zhu, X Wang, H Jin - Cell death & disease, 2022 - nature.com
The growing understanding of RNA functions and their crucial roles in diseases promotes
the application of various RNAs to selectively function on hitherto “undruggable” proteins …
the application of various RNAs to selectively function on hitherto “undruggable” proteins …
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA. 5 Omicron variant in mice
SM Scheaffer, D Lee, B Whitener, B Ying, K Wu… - Nature medicine, 2023 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) …
mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
N Chaudhary, D Weissman… - Nature reviews Drug …, 2021 - nature.com
Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA
vaccines are highly effective at preventing infection and especially severe disease …
vaccines are highly effective at preventing infection and especially severe disease …
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
HM El Sahly, LR Baden, B Essink… - … England Journal of …, 2021 - Mass Medical Soc
Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease …
[PDF][PDF] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Adjuvants are critical for improving the quality and magnitude of adaptive immune
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …